This technology describes the use of thiazolides, a class of FDA-approved antivirals that can cross the blood brain barrier, to treat tauopathic neurodegenerative diseases.
Tau proteins, whose main functionality is to stabilize microtubules, are found along the axons of the neurons in the central nervous system. However, the over-accumulation or hyperphosphorylation of tau proteins can lead to the formation of higher order structures of these proteins in the brain and is related to neurodegenerative diseases such as Alzheimer’s. While there are some small molecule inhibitors, antibodies and vaccines currently undergoing clinical trials, there is currently no approved treatment for tauopathies.
This technology describes an alternative indication for thiazolides in the treatment of neurodegenerative diseases. Thiazolides are a class of small molecule drugs that have already been FDA-approved for use as anti-microbials. One of these, nitazoxanide (NTZ), has been correlated with decreased total tau protein levels in a mouse-embryonic stem cell-derived neuron model, and it has demonstrated efficacy for restoration of memory deficits in a transgenic mouse model for Alzheimer’s. The use of thiazolides as therapeutics could also be expanded to other neurodegenerative tauopathies.
This technology has been validated in mouse models of Alzheimer’s disease.
IR CU18297
Licensing Contact: Jerry Kokoshka